http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=1050110&highlight=Amgen's presentation reviews data demonstrating that ESAs are safe when used appropriately and explains the critical role ESAs play in managing the debilitating effects of anemia in CRF patients. The company's presentation recognizes the potential risks observed in recent experimental trials targeting higher-than-recommended hemoglobin levels, lays out the need for an appropriate hemoglobin target of 10-12 g/dL to guide treatment and manage risk, and highlights the importance of the ongoing Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) to provide answers on the impact of anemia treatment in CRF patients. The company also identifies areas for future study and presents data that suggests that patient response is a stronger risk factor for poor outcomes than ESA dose."Generally patients with poor ESA responsiveness and who receive the highest ESA doses have very poor health status and suffer from multiple co-morbid illnesses," said Dr. Klassen. "It would be expected that these patients would have worse clinical outcomes."